A5040506127- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- Endometrial and Cervical Cancer Treatments
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- Gene expression and cancer classification
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- DNA Repair Mechanisms
- Cancer and Skin Lesions
- Salivary Gland Tumors Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related molecular mechanisms research
- PARP inhibition in cancer therapy
- Bioinformatics and Genomic Networks
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Cervical Cancer and HPV Research
- Uterine Myomas and Treatments
Memorial Sloan Kettering Cancer Center
2016-2025
Kettering University
2013-2024
Hai phong University Of Medicine and Pharmacy
2022
Institute of Oncology Prof. Dr. Ion Chiricuta
2022
County Hospital
2022
Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș
2022
Cornell University
2016-2022
Weill Cornell Medicine
2022
Joint Commission
2022
Yale University
2022
Gene-expression-profiling studies of primary breast tumors performed by different laboratories have resulted in the identification a number distinct prognostic profiles, or gene sets, with little overlap terms identity.To compare predictions derived from these sets for individual samples, we obtained single data set 295 samples and applied five gene-expression-based models: intrinsic subtypes, 70-gene profile, wound response, recurrence score, two-gene ratio (for patients who had been...
The identification of early-stage breast cancer patients at high risk relapse would allow tailoring adjuvant therapy approaches. We assessed whether analysis circulating tumor DNA (ctDNA) in plasma can be used to monitor for minimal residual disease (MRD) cancer. In a prospective cohort 55 early receiving neoadjuvant chemotherapy, detection ctDNA after completion apparently curative treatment-either single postsurgical time point or with serial follow-up samples-predicted metastatic accuracy...
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the genomic alterations present tumours and used monitor progression response treatments. However, patients with brain do not or low amounts ctDNA precluding characterization cancer through ctDNA. Here we show that derived from central nervous system is more abundantly cerebrospinal fluid (CSF) than plasma. Massively parallel sequencing CSF comprehensively characterizes plasma, allowing identification...
Abstract Introduction Breast cancer is a heterogeneous group of tumors, and can be subdivided on the basis histopathological features, genetic alterations gene-expression profiles. One well-defined subtype breast characterized by lack HER2 gene amplification estrogen progesterone receptor expression ('triple-negative tumors'). We examined profile triple-negative tumors to define subgroups with specific characteristics, including risk developing distant metastases. Methods 97 were selected...
Most invasive breast cancers are classified as ductal carcinoma not otherwise specified (IDC NOS), whereas about 25% defined histological 'special types'. These special-type categorized into at least 17 discrete pathological entities; however, whether these also constitute molecular entities remains to be determined. Current therapy decision-making is increasingly governed by the classification of cancer (luminal, basal-like, HER2+). The derived from mainly IDC NOS and it unknown this...
It has been debated for decades how cancer cells acquire metastatic capability. is unclear whether metastases are derived from distinct subpopulations of tumor within the primary site with higher potential, or they originate a random fraction cells. Here we show, by gene expression profiling, that human breast tumors strikingly similar to distant same patient. Unsupervised hierarchical clustering, multidimensional scaling, and permutation testing, as well comparison significantly expressed...
Microarray expression profiling classifies breast cancer into five molecular subtypes: luminal A, B, basal-like, HER2, and normal breast-like. Three microarray-based single sample predictors (SSPs) have been used to define classification of individual samples. We aimed establish agreement between these SSPs for identification subtypes.Previously described were applied one in-house (n=53) three publicly available (n=779) datasets. Agreement was analysed the whole system subtypes individually...
Abstract Purpose: Resistance to platinum-based chemotherapy or PARP inhibition in germline BRCA1 BRCA2 mutation carriers may occur through somatic reversion mutations intragenic deletions that restore function. We assessed whether BRCA1/2 could be identified circulating cell-free DNA (cfDNA) of patients with ovarian breast cancer previously treated platinum and/or inhibitors. Experimental Design: cfDNA from 24 prospectively accrued mutations, including 19 platinum-resistant/refractory and...
Synchronous early-stage endometrioid endometrial carcinomas (EECs) and ovarian (EOCs) are associated with a favorable prognosis have been suggested to represent independent primary tumors rather than metastatic disease. We subjected sporadic synchronous EECs/EOCs from five patients whole-exome massively parallel sequencing, which revealed that the EEC EOC of each case displayed strikingly similar repertoires somatic mutations gene copy number alterations. Despite presence restricted or in...
BRCA1 and BRCA2 are involved in homologous recombination (HR) DNA repair germ-line cancer pre-disposition genes that result a syndrome of hereditary breast ovarian (HBOC). Whether or somatic alterations these other members the HR pathway if mono- bi-allelic HR-related have phenotypic impact on cancers remains to be fully elucidated. Here, we perform pan-cancer analysis The Cancer Genome Atlas (TCGA) data set observe pathogenic repair-related prevalent across many malignancies. These often...